The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Immune-Related Hepatitis: Diagnosis and Management

Checkpoint inhibitor liver toxicity requiring monitoring and intervention

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Immune-Related Hepatitis: Diagnosis and Management?

Immune-related hepatitis results from immune checkpoint inhibitor activation of T-cell responses against hepatocyte antigens.

Incidence ranges from 5 to 10 percent with anti-PD-1/PD-L1 monotherapy and up to 25 to 30 percent with combination immunotherapy.

Onset is typically 6 to 14 weeks after initiation but can occur at any time during or after treatment.

Liver biopsy when performed shows hepatocellular pattern with portal and lobular inflammation; cholestatic patterns are less common.

Severity is graded based on degree of transaminase and bilirubin elevation, presence of liver dysfunction and need for hospitalization.

Symptoms

Most cases are asymptomatic with isolated liver enzyme elevations on routine surveillance.
Fatigue, malaise and decreased appetite may accompany hepatitis.
Right upper quadrant abdominal pain or discomfort can occur.
Jaundice with yellowing of skin and sclera, dark urine and pale stools indicate cholestatic component.
Severe cases may have nausea, vomiting, encephalopathy or coagulopathy in fulminant disease.

Risk Factors

Combination immunotherapy with anti-CTLA-4 and anti-PD-1 increases risk substantially.
Pre-existing liver disease including chronic viral hepatitis B or C, autoimmune hepatitis or hepatic metastases.
Concurrent hepatotoxic medications and herbal supplements.
Recent or active alcohol use.
Higher cumulative immunotherapy doses and treatment duration.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Significant elevation of transaminases above 5 times upper limit of normal or bilirubin above 1.5 times upper limit warrants urgent evaluation.
  • New jaundice, dark urine, severe fatigue or right upper quadrant pain during therapy needs prompt assessment.
  • Signs of hepatic decompensation including encephalopathy, coagulopathy or ascites are emergencies.
  • Persistent enzyme elevations despite corticosteroid therapy require treatment intensification and biopsy consideration.
  • Long-term follow-up monitors for recovery, recurrence and chronic liver dysfunction.

Treatment Methods

01
Grade 1 mild elevations may warrant continued therapy with closer monitoring.
02
Grade 2 with moderate elevations requires holding immunotherapy and starting prednisone 0.5 to 1 mg/kg/day.
03
Grade 3 to 4 severe hepatitis necessitates permanent discontinuation, hospitalization and methylprednisolone 1 to 2 mg/kg/day intravenously.
04
Refractory cases with no improvement in 3 days may require mycophenolate mofetil; infliximab is contraindicated due to hepatotoxicity.
05
Comprehensive evaluation excludes viral hepatitis, autoimmune disease, drug-induced injury and disease progression; liver biopsy in selected cases; gradual corticosteroid taper over 4 weeks with hepatology consultation completes management.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.